| Autor: |
Nickolas Papadopoulos, Nianqing Xiao, Robert A. Anders, Kristen K. Ciombor, Shibin Zhou, Katherine M. Bever, Cara Wilt, Bao H. Lam, Hao Wang, Janis M. Taube, George A. Fisher, Matthias Holdhoff, Fay Wong, Richard M. Goldberg, Amanda N. Fader, Ludmila Danilova, Jennifer N. Durham, Laveet K. Aulakh, David Spetzler, Leslie Cope, Dung T. Le, Christian F. Meyer, Franck Housseau, James J. Lee, Aleksandra Eyring, Andrew K. Joe, James R. Eshleman, Deborah K. Armstrong, Bjarne Bartlett, Kellie N. Smith, Brandon Luber, Agnieszka A. Rucki, Daniel A. Laheru, Steve Lu, Nilofer S. Azad, Todd S. Crocenzi, Kenneth W. Kinzler, Tim F. Greten, Austin G. Duffy, Bert Vogelstein, Drew M. Pardoll, Luis A. Diaz, Atif Zaheer, Holly Kemberling, S. Peter Kang, Ross C. Donehower |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Popis: |
Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase 2 clinical trial, Le et al. showed that treatment success is not just limited to colon cancer (see the Perspective by Goswami and Sharma). They found that a wide range of different cancer types with MMR deficiency also responded to PD-1 blockade. The trial included some patients with pancreatic cancer, which is one of the deadliest forms of cancer. The clinical trial is still ongoing, and around 20% of patients have so far achieved a complete response. MMR deficiency appears to be a biomarker for predicting successful treatment outcomes for several solid tumors and indicates a new therapeutic option for patients harboring MMR-deficient cancers. Science , this issue p. 409 ; see also p. 358 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
